Zydus Lifesciences Limited (BOM:532321)

Zydus Lifesciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	50,400	45,255	38,595	19,603	44,873
Depreciation & Amortization	13,705	8,868	7,345	6,965	7,086
Other Amortization	375	290	296	262	275
Loss (Gain) From Sale of Assets	-23	-345	-169	-208	-1,110
Asset Writedown & Restructuring Costs	-	2,196	177	6,042	-
Loss (Gain) From Sale of Investments	-292	-650	-409	-483	-751
Provision & Write-off of Bad Debts	325	299	206	17	41
Other Operating Activities	-17,087	-3,461	-5,343	-2,882	-25,229
Change in Accounts Receivable	-8,581	11,957	-7,472	-8,485	-1,817
Change in Inventory	-4,124	-4,449	-20	4,407	-5,255
Change in Accounts Payable	-7,951	735	-476	-1,708	-1,203
Change in Other Net Operating Assets	-5,581	7,116	-1,059	3,428	4,915
Operating Cash Flow	21,166	67,811	31,963	26,888	21,045
Operating Cash Flow Growth	-68.79%	112.16%	18.88%	27.76%	-36.11%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-33,940	-16,937	-9,066	-10,309	-12,026
Sale of Property, Plant & Equipment	249	514	237	394	354
Cash Acquisitions	-58,793	-3,690	-7,201	-	-
Divestitures	-	-	-	400	-
Sale (Purchase) of Intangibles	-	-	-	-	1,127
Investment in Securities	-11,164	-50,168	-18	24,113	-28,633
Other Investing Activities	19,955	-12,541	1,287	776	29,175
Investing Cash Flow	-82,961	-83,578	-14,752	15,350	-10,003

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	11,892	24,020	-	-	2,907
Long-Term Debt Issued	70,710	-	14	1,585	7,464
Total Debt Issued	82,602	24,020	14	1,585	10,371
Short-Term Debt Repaid	-	-	-3,102	-23,064	-
Long-Term Debt Repaid	-9,934	-147	-827	-9,960	-14,221
Total Debt Repaid	-9,934	-147	-3,929	-33,024	-14,221
Net Debt Issued (Repaid)	72,668	23,873	-3,915	-31,439	-3,850
Repurchase of Common Stock	-	-	-7,250	-8,632	-
Common Dividends Paid	-11,063	-3,025	-6,210	-2,671	-3,722
Other Financing Activities	-3,536	-895	-413	-1,262	-1,111
Financing Cash Flow	58,069	19,953	-17,788	-44,004	-8,683

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	2,108	-214	-231	66	86
Miscellaneous Cash Flow Adjustments	1,902	166	60	-	-259
Net Cash Flow	284	4,138	-748	-1,700	2,186

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-12,774	50,874	22,897	16,579	9,019
Free Cash Flow Growth	-	122.19%	38.11%	83.82%	-63.03%
Free Cash Flow Margin	-4.71%	21.89%	11.71%	9.62%	5.97%
Free Cash Flow Per Share	-12.70	50.56	22.63	16.32	8.81
Levered Free Cash Flow	-9,062	28,617	16,057	10,611	7,540
Unlevered Free Cash Flow	-6,780	29,201	16,332	11,395	8,255

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	3,536	895	413	1,262	1,111
Cash Income Tax Paid	15,910	18,019	12,858	5,920	6,746
Change in Working Capital	-26,237	15,359	-9,027	-2,358	-3,360

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error